PDGFRB and glioblastoma: One study showed that treating EGFRvIII-expressing GBM cells with the CL4 aptamer (anti-EGFR) led to the upregulation of PDGFRβ as a resistance mechanism, implying that a dual-aptamer therapy (EGFR + PDGFRβ) could be more effective.37